{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T03:39:59Z","timestamp":1764905999208,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.gore.2021.100739","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T22:58:18Z","timestamp":1614639498000},"page":"100739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Guillain-Barre Syndrome in a patient with uterine adenocarcinoma undergoing treatment with immune-checkpoint inhibitor therapy: A case report and review of the literature"],"prefix":"10.1016","volume":"36","author":[{"given":"Bogna N.","family":"Brzezinska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2630-7337","authenticated-orcid":false,"given":"Robert V.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bunja","family":"Rungruang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.gore.2021.100739_b0005","first-page":"340","article-title":"Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors","volume":"6","author":"Anderson","year":"2019","journal-title":"Neurooncol. Pract."},{"issue":"3","key":"10.1016\/j.gore.2021.100739_b0010","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"137","author":"Fellner","year":"2018","journal-title":"J. Neurooncol."},{"issue":"1","key":"10.1016\/j.gore.2021.100739_b0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3892\/mco.2020.2042","article-title":"Guillain-Barre syndrome induced by pembrolizumab and sunitinib: a case report","volume":"13","author":"Han","year":"2020","journal-title":"Mol. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2021.100739_b0020","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr. Opin. Neurol."},{"issue":"10","key":"10.1016\/j.gore.2021.100739_b0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.gore.2021.100739_b0030","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/EDBK_237967","article-title":"Immunotherapy in gynecologic cancers: what we know now and where we are headed","volume":"39","author":"Levinson","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"9","key":"10.1016\/j.gore.2021.100739_b0035","first-page":"e3371","article-title":"Case reports of pembrolizumab-induced acute inflammatory demyelinating polyneuropathy","volume":"10","author":"Manam","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.gore.2021.100739_b0040","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26101","article-title":"Guillain-Barr\u00e9-like syndrome during pembrolizumab treatment","author":"Ong","year":"2018","journal-title":"Muscle Nerve"},{"issue":"Suppl. 2","key":"10.1016\/j.gore.2021.100739_b0045","first-page":"S74","article-title":"Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment","volume":"24","author":"Psimaras","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"12","key":"10.1016\/j.gore.2021.100739_b0050","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578921000448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578921000448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:57:16Z","timestamp":1762480636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578921000448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":10,"alternative-id":["S2352578921000448"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2021.100739","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guillain-Barre Syndrome in a patient with uterine adenocarcinoma undergoing treatment with immune-checkpoint inhibitor therapy: A case report and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2021.100739","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100739"}}